penicillamine has been researched along with Disease Exacerbation in 34 studies
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.
penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "D: -Penicillamine-induced pemphigus occurs infrequently, typically in patients with rheumatoid arthritis." | 7.70 | Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis. ( Jimenez, S; Shapiro, M; Werth, VP, 2000) |
| "We present 3 cases of anti-myeloperoxidase, anti-neutrophil cytoplasmic antibody (MPO-ANCA)-positive rapidly progressive glomerulonephritis developed during the treatment with D-penicillamine (D-PC) for rheumatoid arthritis." | 7.70 | Rapidly progressive glomerulonephritis with D-penicillamine. ( Akama, H; Kamatani, N; Nanke, Y; Terai, C, 2000) |
| "Ursodeoxycholic acid (UDCA) is a beneficial medical therapy for patients with PBC." | 6.69 | Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. ( Angulo, P; Batts, KP; Dickson, ER; Jorgensen, RA; Lindor, KD; Therneau, TM, 1999) |
| "Because Wilson disease was never associated with ANCA-related nephritis, this case strongly supports that d-penicillamine can induce ANCA-vasculitis." | 5.34 | D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease. ( Bienaimé, F; Clerbaux, G; Mougenot, B; Plaisier, E; Ronco, P; Rougier, JP, 2007) |
| "D: -Penicillamine-induced pemphigus occurs infrequently, typically in patients with rheumatoid arthritis." | 3.70 | Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis. ( Jimenez, S; Shapiro, M; Werth, VP, 2000) |
| "We present 3 cases of anti-myeloperoxidase, anti-neutrophil cytoplasmic antibody (MPO-ANCA)-positive rapidly progressive glomerulonephritis developed during the treatment with D-penicillamine (D-PC) for rheumatoid arthritis." | 3.70 | Rapidly progressive glomerulonephritis with D-penicillamine. ( Akama, H; Kamatani, N; Nanke, Y; Terai, C, 2000) |
| "Ursodeoxycholic acid (UDCA) is a beneficial medical therapy for patients with PBC." | 2.69 | Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. ( Angulo, P; Batts, KP; Dickson, ER; Jorgensen, RA; Lindor, KD; Therneau, TM, 1999) |
| "Hereditary hemochromatosis and Wilson disease are autosomal recessive storage disorders of iron and copper overload, respectively." | 2.50 | Metal storage disorders: Wilson disease and hemochromatosis. ( Kanwar, P; Kowdley, KV, 2014) |
| "Stiff skin syndrome is a sclerodermalike disorder that presents in infancy or early childhood with rock-hard skin, limited joint mobility, and mild hypertrichosis in the absence of visceral or muscle involvement, immunologic abnormalities, or vascular hyperreactivity." | 2.44 | The stiff skin syndrome: case series, differential diagnosis of the stiff skin phenotype, and review of the literature. ( Connolly, MK; Frieden, IJ; Gilliam, AE; Liu, T; McCalmont, TH; Williams, ML, 2008) |
| "Ursodeoxycholic acid has been shown to improve survival free of transplantation in a conclusive fashion." | 2.40 | Management of primary biliary cirrhosis and autoimmune cholangitis. ( Angulo, P; Lindor, KD, 1998) |
| "After admission, she developed hepatic encephalopathy and was diagnosed with fulminant hepatitis based on the American Association for the Study of Liver Disease (AASLD) position paper." | 1.48 | Clinically diagnosed late-onset fulminant Wilson's disease without cirrhosis: A case report. ( Amano, T; Fukui, K; Hayashi, S; Inada, M; Matsubara, T; Mukai, K; Nakajima, S; Nishida, T; Shimakoshi, H; Shimoda, A; Sugimoto, A; Takahashi, K; Yamamoto, M, 2018) |
| "Patients with neurologic Wilson disease (NWD) may worsen on treatment, but there is no study evaluating the role of oxidative stress." | 1.42 | Role of Oxidative Stress in the Worsening of Neurologic Wilson Disease Following Chelating Therapy. ( Kalita, J; Kumar, V; Misra, UK; Ranjan, A, 2015) |
| "Glioblastoma is a highly vascularized brain tumor, and antiangiogenic therapy improves its progression-free survival." | 1.39 | Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression. ( Jiang, A; Jiang, E; Kieran, MW; Mammoto, A; Mammoto, T; Panigrahy, D, 2013) |
| "To evaluate Wilson's disease (WD) features in Sardinian patients with Kayser-Fleischer (KF) ring and to evaluate correlations between modifications in KF and anti-copper therapy and systemic WD evolution." | 1.38 | Kayser-Fleischer ring in Wilson's disease: a cohort study. ( Civolani, A; Demelia, E; Demelia, L; Fenu, M; Liggi, M; Sorbello, O, 2012) |
| "Those with neurological Wilson's disease gave an intermediate figure (305." | 1.37 | The pattern of urinary copper excretion and its response to treatment in patients with Wilson's disease. ( Walshe, JM, 2011) |
| "Wilson disease is a disorder of copper metabolism characterized by copper overload." | 1.35 | Effect of D-penicillamine on liver fibrosis and inflammation in Wilson disease. ( Bahador, A; Dehghani, M; Dehghani, SM; Geramizadeh, B; Kakaei, F; Kazemi, K; Malek-Hosseini, SA; Nikeghbalian, S; Reza Nejatollahi, SM; Salahi, H, 2008) |
| "Because Wilson disease was never associated with ANCA-related nephritis, this case strongly supports that d-penicillamine can induce ANCA-vasculitis." | 1.34 | D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease. ( Bienaimé, F; Clerbaux, G; Mougenot, B; Plaisier, E; Ronco, P; Rougier, JP, 2007) |
| "We report 21 cases of Wilson's disease with neurological complications, emphasizing clinical semiology, diagnostic means and problems of the therapeutics in our country." | 1.31 | [Wilson's disease. Clinical presentation, treatment and evolution in 21 cases]. ( Aïdi, S; Benomar, A; Bono, W; Chkili, T; el Alaoui-Faris, M; Moutie, O; Yahyaoui, M, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (17.65) | 18.2507 |
| 2000's | 17 (50.00) | 29.6817 |
| 2010's | 10 (29.41) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, XQ | 1 |
| Li, LY | 1 |
| Yang, WM | 1 |
| Wang, Y | 1 |
| Amano, T | 1 |
| Matsubara, T | 1 |
| Nishida, T | 1 |
| Shimakoshi, H | 1 |
| Shimoda, A | 1 |
| Sugimoto, A | 1 |
| Takahashi, K | 1 |
| Mukai, K | 1 |
| Yamamoto, M | 1 |
| Hayashi, S | 1 |
| Nakajima, S | 1 |
| Fukui, K | 1 |
| Inada, M | 1 |
| Mammoto, T | 1 |
| Jiang, A | 1 |
| Jiang, E | 1 |
| Panigrahy, D | 1 |
| Kieran, MW | 1 |
| Mammoto, A | 1 |
| Kanwar, P | 1 |
| Kowdley, KV | 1 |
| Kalita, J | 1 |
| Kumar, V | 1 |
| Ranjan, A | 1 |
| Misra, UK | 1 |
| Dubbioso, R | 1 |
| Ranucci, G | 1 |
| Esposito, M | 1 |
| Di Dato, F | 1 |
| Topa, A | 1 |
| Quarantelli, M | 1 |
| Matarazzo, M | 1 |
| Santoro, L | 1 |
| Manganelli, F | 1 |
| Iorio, R | 1 |
| Liu, T | 1 |
| McCalmont, TH | 1 |
| Frieden, IJ | 1 |
| Williams, ML | 1 |
| Connolly, MK | 1 |
| Gilliam, AE | 1 |
| Cox, D | 1 |
| O' Regan, G | 1 |
| Collins, S | 1 |
| Byrne, A | 1 |
| Irvine, A | 1 |
| Watson, R | 1 |
| Yukawa, N | 1 |
| Mimori, T | 1 |
| Kazemi, K | 1 |
| Geramizadeh, B | 1 |
| Nikeghbalian, S | 1 |
| Salahi, H | 1 |
| Bahador, A | 1 |
| Reza Nejatollahi, SM | 1 |
| Dehghani, SM | 1 |
| Dehghani, M | 1 |
| Kakaei, F | 1 |
| Malek-Hosseini, SA | 1 |
| Amjadi, S | 1 |
| Maranian, P | 1 |
| Furst, DE | 2 |
| Clements, PJ | 2 |
| Wong, WK | 2 |
| Postlethwaite, AE | 1 |
| Khanna, PP | 1 |
| Khanna, D | 1 |
| Bruha, R | 1 |
| Marecek, Z | 1 |
| Pospisilova, L | 1 |
| Nevsimalova, S | 1 |
| Vitek, L | 1 |
| Martasek, P | 1 |
| Nevoral, J | 1 |
| Petrtyl, J | 1 |
| Urbanek, P | 1 |
| Jiraskova, A | 1 |
| Ferenci, P | 1 |
| Walshe, JM | 1 |
| Peña-Quintana, L | 1 |
| García-Luzardo, MR | 1 |
| García-Villarreal, L | 1 |
| Arias-Santos, MD | 1 |
| Garay-Sánchez, P | 1 |
| Santana, A | 1 |
| González-Santana, D | 1 |
| Ramos-Varela, JC | 1 |
| Rial-González, R | 1 |
| Tugores, A | 1 |
| Fenu, M | 1 |
| Liggi, M | 1 |
| Demelia, E | 1 |
| Sorbello, O | 2 |
| Civolani, A | 2 |
| Demelia, L | 2 |
| Sini, M | 1 |
| Sanna, F | 1 |
| Battolu, F | 1 |
| Fanni, D | 1 |
| Faa, G | 1 |
| Angulo, P | 3 |
| Lindor, KD | 4 |
| Członkowska, A | 1 |
| Tarnacka, B | 1 |
| Litwin, T | 1 |
| Gajda, J | 1 |
| Rodo, M | 1 |
| Aikath, D | 1 |
| Gupta, A | 1 |
| Chattopadhyay, I | 1 |
| Hashmi, MA | 1 |
| Gangopadhyay, PK | 1 |
| Das, SK | 1 |
| Ray, K | 1 |
| Sohtaoglu, M | 1 |
| Ergin, H | 1 |
| Ozekmekçi, S | 1 |
| Gökdemir, S | 1 |
| Sonsuz, A | 1 |
| Arici, C | 1 |
| Streisand, JB | 1 |
| Sinha, S | 2 |
| Taly, AB | 2 |
| Prashanth, LK | 2 |
| Ravishankar, S | 2 |
| Arunodaya, GR | 1 |
| Vasudev, MK | 2 |
| Bienaimé, F | 1 |
| Clerbaux, G | 1 |
| Plaisier, E | 1 |
| Mougenot, B | 1 |
| Ronco, P | 1 |
| Rougier, JP | 1 |
| van der Heide, A | 1 |
| Jacobs, JW | 1 |
| Schenk, Y | 1 |
| Bijlsma, JW | 1 |
| Locke, GR | 1 |
| Therneau, TM | 3 |
| Ludwig, J | 1 |
| Dickson, ER | 2 |
| Batts, KP | 2 |
| Jorgensen, RA | 1 |
| Brewer, GJ | 1 |
| Larson, DR | 1 |
| LaRusso, NF | 1 |
| Shapiro, M | 1 |
| Jimenez, S | 1 |
| Werth, VP | 1 |
| Nanke, Y | 1 |
| Akama, H | 1 |
| Terai, C | 1 |
| Kamatani, N | 1 |
| Cozzi, F | 1 |
| Marson, P | 1 |
| Rosada, M | 1 |
| De Silvestro, G | 1 |
| Bullo, A | 1 |
| Punzi, L | 1 |
| Todesco, S | 1 |
| Squitti, R | 1 |
| Rossini, PM | 1 |
| Cassetta, E | 1 |
| Moffa, F | 1 |
| Pasqualetti, P | 1 |
| Cortesi, M | 1 |
| Colloca, A | 1 |
| Rossi, L | 1 |
| Finazzi-Agró, A | 1 |
| Bono, W | 1 |
| Moutie, O | 1 |
| Benomar, A | 1 |
| Aïdi, S | 1 |
| el Alaoui-Faris, M | 1 |
| Yahyaoui, M | 1 |
| Chkili, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Security of Bezafibrate in Patients With Primary Biliary Cirrhosis Without Biochemical Response to Ursodeoxycholic Acid: A Randomized, Double-blind, Placebo-controlled Trial[NCT02937012] | Phase 3 | 34 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for penicillamine and Disease Exacerbation
| Article | Year |
|---|---|
Metal storage disorders: Wilson disease and hemochromatosis.
Topics: Biopsy; Chelating Agents; Disease Progression; Genetic Predisposition to Disease; Genetic Testing; H | 2014 |
The stiff skin syndrome: case series, differential diagnosis of the stiff skin phenotype, and review of the literature.
Topics: Age Distribution; Biopsy, Needle; Child; Child, Preschool; Disease Progression; Fascia; Female; Huma | 2008 |
[Effect of disease modifying anti-rheumatic drugs on radiographic progression in rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Cysteine; Disease Progression; Drug Thera | 2009 |
Management of primary biliary cirrhosis and autoimmune cholangitis.
Topics: Adrenal Cortex Hormones; Autoimmune Diseases; Cholangitis; Colchicine; Disease Progression; Drug The | 1998 |
6 trials available for penicillamine and Disease Exacerbation
| Article | Year |
|---|---|
Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.
Topics: Adult; Age of Onset; Animals; Antirheumatic Agents; Cattle; Collagen Type I; Disease Progression; Fe | 2009 |
Endpoint measures in rheumatoid arthritis clinical trials: group summary and individual patient analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Data Interpretation, Statistical; Disability Evaluation | 1994 |
Time course of histological progression in primary biliary cirrhosis.
Topics: Biopsy; Disease Progression; Double-Blind Method; Female; Humans; Liver; Liver Cirrhosis, Biliary; M | 1996 |
Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
Topics: Adult; Aged; Cholagogues and Choleretics; Disease Progression; Female; Humans; Liver Cirrhosis; Live | 1999 |
Long-term therapy with plasma exchange in systemic sclerosis: effects on laboratory markers reflecting disease activity.
Topics: Adult; Aged; Antibody Specificity; Autoantibodies; Autoimmune Diseases; Biomarkers; Combined Modalit | 2001 |
d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chelating Agents; Copper; Disease Progression; Female; H | 2002 |
24 other studies available for penicillamine and Disease Exacerbation
| Article | Year |
|---|---|
Combined dimercaptosuccinic acid and zinc treatment in neurological Wilson's disease patients with penicillamine-induced allergy or early neurological deterioration.
Topics: Adolescent; Adult; Brain; Chelating Agents; Child; Disease Progression; Drug Hypersensitivity; Drug | 2020 |
Clinically diagnosed late-onset fulminant Wilson's disease without cirrhosis: A case report.
Topics: Age of Onset; Biopsy; Bone Marrow Examination; Disease Progression; Fatal Outcome; Female; Hepatic E | 2018 |
Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression.
Topics: Animals; Brain; Brain Neoplasms; Cell Count; Cell Line, Tumor; Collagen; Disease Progression; Gliobl | 2013 |
Role of Oxidative Stress in the Worsening of Neurologic Wilson Disease Following Chelating Therapy.
Topics: Adolescent; Adult; Antioxidants; Chelating Agents; Chelation Therapy; Child; Child, Preschool; Coppe | 2015 |
Subclinical neurological involvement does not develop if Wilson's disease is treated early.
Topics: Adenosine Triphosphatases; Adolescent; Adult; Analysis of Variance; Brain; Cation Transport Proteins | 2016 |
Juvenile localised scleroderma: a retrospective review of response to systemic treatment.
Topics: Adolescent; Adolescent Medicine; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antirheumatic Ag | 2008 |
Effect of D-penicillamine on liver fibrosis and inflammation in Wilson disease.
Topics: Adolescent; Adult; Chelating Agents; Child; Child, Preschool; Copper; Disease Progression; Female; H | 2008 |
Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation.
Topics: Adenosine Triphosphatases; Adolescent; Adult; Asymptomatic Diseases; Cation Transport Proteins; Chel | 2011 |
The pattern of urinary copper excretion and its response to treatment in patients with Wilson's disease.
Topics: Adolescent; Adult; Chelating Agents; Chelation Therapy; Child; Child, Preschool; Copper; Disease Pro | 2011 |
Manifestations and evolution of Wilson disease in pediatric patients carrying ATP7B mutation L708P.
Topics: Adenosine Triphosphatases; Adolescent; Cation Transport Proteins; Ceruloplasmin; Chelating Agents; C | 2012 |
Kayser-Fleischer ring in Wilson's disease: a cohort study.
Topics: Adolescent; Adult; Brain; Chelating Agents; Cohort Studies; Disease Progression; Female; Hepatolenti | 2012 |
Histologic evolution and long-term outcome of Wilson's disease: results of a single-center experience.
Topics: Adolescent; Adult; Biopsy; Chelating Agents; Chi-Square Distribution; Child; Child, Preschool; Disea | 2013 |
Wilson's disease-cause of mortality in 164 patients during 1992-2003 observation period.
Topics: Adult; Brain; Confidence Intervals; Copper; Disease Progression; Female; Hepatolenticular Degenerati | 2005 |
Subcortical white matter abnormalities related to drug resistance in Wilson disease.
Topics: Adenosine Triphosphatases; Antidotes; Brain; Cation Transport Proteins; Child; Copper-Transporting A | 2006 |
Patient with late-onset Wilson's disease: deterioration with penicillamine.
Topics: Age Factors; Aged; Chelating Agents; Disease Progression; Fatal Outcome; Female; Hepatolenticular De | 2007 |
Assessing disease progression using a composite endpoint.
Topics: Antirheumatic Agents; Data Interpretation, Statistical; Disease Progression; Endpoint Determination; | 2007 |
Sequential MRI changes in Wilson's disease with de-coppering therapy: a study of 50 patients.
Topics: Adolescent; Adult; Astringents; Chelating Agents; Child; Disease Progression; Female; Health Status | 2007 |
Central pontine signal changes in Wilson's disease: distinct MRI morphology and sequential changes with de-coppering therapy.
Topics: Adolescent; Adult; Astringents; Chelating Agents; Chi-Square Distribution; Child; Disease Progressio | 2007 |
D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease.
Topics: Adult; Antibodies, Antineutrophil Cytoplasmic; Chelating Agents; Creatinine; Disease Progression; Fe | 2007 |
Penicillamine should not be used as initial therapy in Wilson's disease.
Topics: Chelating Agents; Copper; Disease Progression; Hepatolenticular Degeneration; Humans; Penicillamine | 1999 |
Time course of histological progression in primary sclerosing cholangitis.
Topics: Adolescent; Adult; Aged; Biopsy; Cholagogues and Choleretics; Cholangitis, Sclerosing; Disease Progr | 1999 |
Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis.
Topics: Aged; Antirheumatic Agents; Disease Progression; Female; Humans; Pemphigus; Penicillamine; Scleroder | 2000 |
Rapidly progressive glomerulonephritis with D-penicillamine.
Topics: Adult; Antibodies, Antineutrophil Cytoplasmic; Antirheumatic Agents; Arthritis, Rheumatoid; Disease | 2000 |
[Wilson's disease. Clinical presentation, treatment and evolution in 21 cases].
Topics: Adolescent; Adult; Antirheumatic Agents; Copper; Disease Progression; Female; Hepatolenticular Degen | 2002 |